...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways
【24h】

A light-triggered self-reinforced nanoagent for targeted chemo-photodynamic therapy of breast cancer bone metastases via ER stress and mitochondria mediated apoptotic pathways

机译:通过ER应激和线粒体介导的凋亡途径的乳腺癌骨转移患者乳腺癌骨转移的靶向化学光动力学治疗的光触发的自增强纳米型

获取原文
获取原文并翻译 | 示例
           

摘要

Current therapeutic strategies for the treatment of bone metastases are often limited by the lack of selectivity, severe systemic toxicity and suboptimal efficacy. Nanomedicine meditated chemo-photodynamic therapy provides a promising therapeutic opportunity for enhanced cancer therapy. Herein, we constructed an alendronate (ALN)-functionalized bone-seeking nanoagent (BTZ@ZnPc-ALN) to co-deliver the proteasome inhibitor bortezomib (BTZ) and the photosensitizer Zinc phthalocyanine (ZnPc) for synergistic chemo-photodynamic therapy of bone metastases. Results showed that BTZ@ZnPc-ALN possessed favorable bone affinity both in vitro and in vivo and could release drug in a pH-responsive manner. Under irradiation, BTZ@ZnPc-ALN could generate reactive oxygen species (ROS) to cause mitochondrial damage, and increase the cytosolic Ca2+ levels and the expression of GRP78 protein to induce excessive endoplasmic reticulum (ER) stress, thereby synergistically inhibiting cell proliferation. More importantly, BTZ@ZnPc-ALN could prolong blood circulation time and preferentially navigate to the bone affected site. As a result, tumor growth was significantly inhibited by bone targeted chemo-photodynamic therapy, with tumor volume cut down by 85% compared with PBS group and bone remained undamaged. Besides, the systemic toxicity of BTZ was significantly reduced. Therefore, the versatile nanoagent is expected to be a promising nanoplatform to concern multiple intracellular stress for remarkable synergistic chemo-photodynamic therapy of bone metastases.
机译:目前用于治疗骨转移的治疗策略通常受到缺乏选择性,严重的全身毒性和次优疗效的限制。 Nanomedicine冥想的化学光动力疗法为增强的癌症治疗提供了有希望的治疗机会。在此,我们构建了一族(ALN) - 官能化的骨头纳米型(BTZ @ ZnPC-ALN),共同递送蛋白酶体抑制剂Bortezomib(BTZ)和光敏剂锌酞菁(ZnPC),用于骨转移的协同化学光敏性治疗。结果表明,BTZ @ ZnPC-ALN在体外和体内都具有良好的骨亲和性,并且可以以pH响应的方式释放药物。在辐照下,BTZ @ ZnPC-ALN可以产生反应性氧物质(ROS)以引起线粒体损伤,并增加胞质CA2 +水平和GRP78蛋白的表达,以诱导过量的内质网(ER)应激,从而协同抑制细胞增殖。更重要的是,BTZ @ ZnPC-ALN可以延长血液循环时间并优先导航到骨影响的部位。结果,通过骨靶向化学光动力治疗显着抑制肿瘤生长,与PBS组和骨骼保持未损坏,肿瘤体积减少85%。此外,BTZ的全身毒性显着降低。因此,预期通用的纳米型是一种有前途的纳米片,以涉及骨转移的显着协同化学光动力学治疗的多种细胞内应力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号